On November 23, 2021 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported that it will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021 (Press release, Myovant Sciences, NOV 23, 2021, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-participate-evercore-isi-4th-annual-healthconx [SID1234595965]). David Marek, Chief Executive Officer of Myovant Sciences, Inc. will participate in a fireside chat at 11:45 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to the Evercore fireside chat, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

On November 23, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in the following virtual investor conferences in December (Press release, CRISPR Therapeutics, NOV 23, 2021, View Source [SID1234595964]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

4th Annual Evercore ISI HealthCONx Conference
Date: Wednesday, December 1, 2021
Time: 12:35 p.m. ET

Piper Sandler 33rd Annual Healthcare Conference
Date: Thursday, December 2, 2021
Time: 1:00 p.m. ET

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcasts will be archived on the Company’s website for 14 days following each presentation.

On November 23, 2021 AbbVie (NYSE: ABBV) reported that it will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021 (Press release, AbbVie, NOV 23, 2021, View Source [SID1234595963]). Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 11:10 a.m. CT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On November 23, 2021 IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, reported that IMV’s executive management team will be participating in the upcoming Piper Sandler Virtual Healthcare Conference (Press release, IMV, NOV 23, 2021, View Source [SID1234595962]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On-demand starting Tuesday, November 23, 2021
11:00 a.m. ET
Format: Fireside chat
Actual conference: November 30 – December 2, 2021
A webcast of this presentation will be accessible in the ‘Events, Webcasts & Presentations’ section of IMV’s website. The webcast will then be archived, and a copy of the presentation will be available at www.imv-inc.com.

On November 23, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that the Company’s management team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 2:40 p.m. ET (Press release, Mersana Therapeutics, NOV 23, 2021, View Source [SID1234595961]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.